Schrödinger (SDGR) on Friday announced a collaboration with Eli Lilly (LLY) to integrate its drug development software LiveDesign with the Indiana-based pharma giant’s TuneLab AI-based drug discovery platform.
Accordingly, LiveDesign, Schrödinger’s enterprise informatics platform, will become a priority interface for biotech firms accessing LLY’s TuneLab, which leverages AI capabilities to accelerate drug discovery.
The New York-based company said that a third party will host TuneLab in its platform, making sure that LLY and its partner firms can keep their proprietary data secure thanks to a privacy-focused method called federated learning.
“We are pleased to be partnering with Lilly to expand the use of digital drug design methods and ultimately drive greater impact for patients,” added Karen Akinsanya, SDGR’s president of R&D, therapeutics, and chief strategy officer, partnerships.